@Mozzarc and@Babbanap
Thanks for your responses.
I am 100% on board about the utility and intrinsic value of the drug.
I think we all know there are no guarantees at this point and we will have to wait and see what the regulatory and potential funding partners do and when.
I do think that risk to getting timely funding is what tempers my enthusiasm and means I weigh the amount to hold and add at this juncture against my other portfolio holdings in terms of risk.
Now we wait...
GLTAH
research reports and media, page-4392
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
0.060(29.3%) |
Mkt cap ! $92.81M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 26.5¢ | 21.0¢ | $862.8K | 3.580M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7500 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 9999 | 1 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |